Taysha Gene Therapies Announces Fast Track Designation Granted by US FDA for TSHA-102 in Rett Syndrome

Taysha Gene Therapies, Inc. announced the US FDA has granted Fast Track Designation to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.